ReviewNeuro-oncology advances2026
Chemotherapy neurotoxicity and aging: Uncovering shared central nervous system pathologies and potential interventions.
Review in Neuro-oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The neurobiology of survivorship: Cognitive consequences of modern oncology.Neuro-oncology advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in cancer therapies have significantly improved survival rates, but many survivors face persistent cognitive impairments collectively termed chemotherapy-related cognitive impairment (CRCI). Symptoms such as memory deficits, reduced attention, impaired executive function, and slowed information processing can profoundly affect quality of life, often persisting for years or even decades. The cellular and molecular mechanisms underlying CRCI remain poorly understood, but accumulating evidence suggests that cancer therapy accelerates aging-like processes in the brain. This review positions CRCI as a model of induced aging and neurodegeneration, emphasizing shared central nervous system (CNS) pathologies with aging such as neuroinflammation, blood-brain barrier disruptions, reduced neurogenesis, hypomyelination, and cellular senescence, providing a novel framework for investigating CRCI. This review highlights the parallels between CRCI and aging, proposing that insights from aging research can inform the development of targeted interventions to mitigate CNS-related CRCI symptoms. Addressing these shared mechanisms may lead to innovative therapies that improve cognitive outcomes and enhance the quality of life for cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.